Previous 10 | Next 10 |
Gainers: Asensus Surgical ASXC +37%, Nabriva Therapeutics (NBRV) +29%, Kintara Therapeutics KTRA +26%, Owens & Minor (OMI) +21%, Protagenic Therapeutics (PTIX) +10%.Losers: Larimar Therapeutics LRMR -37%, Travere Therapeutics TVTX ...
IAC/InterActiveCorp (IAC) -31%.Novan (NOVN) -18% on announcing 1-for-10 reverse stock split.Petros Pharmaceuticals (PTPI) -18%.Achieve Life Sciences (ACHV) -15% on proposing stock offeringLordstown Motors (RIDE) -13% on Q1 earnings releaseCreative Realities (CREX...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nvidia (NASDAQ: NVDA ) stock is on the rise Monday after the company announced plans for a stock split. Source: JHVEPhoto / Shutterstock.com Here’s everything investors in NVDA stock need to know about...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Scopus Biopharma (NASDAQ: SCPS ) and SCPS stock are seeing incredible gains. This stock has moved more than 115% higher at the time of writing on extremely heavy volume. Source: ...
Gainers: Scopus BioPharma (SCPS) +97%.MMA Capital (MMAC) +58%.Aptorum (APM) +37%.Creative Realities (CREX) +33%.Obalon Therapeutics (OBLN) +30%.Regional Health Properties (RHE) +24%.Taiwan Liposome (TLC) +21%.Virgin Galactic (SPCE) +19%.Verastem (VSTM) +18%.Veritiv (VRTV) +17%.Loser...
Scopus BioPharma Inc. ( NASDAQ: SCPS ) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the s...
Biotech Penny Stocks To Watch After Bullish Analyst Ratings This weekend we discussed how analyst ratings could play a role with penny stocks. Also, reports that accompany them shed light on the future outlook and potential catalysts these firms have an interest in. When it comes to fin...
Scopus BioPharma Inc. (NASDAQ: SCPS) has reported approval of an investigational new drug application by the U.S. FDA for CpG-STAT3siRNA, the immune-oncology RNA therapy to treat multiple cancers. Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City...
The FDA has approved Scopus BioPharma's ([[SCPS]] +109.7%) investigational new drug application ((IND)) for CpG-STAT3siRNA, the distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at Cit...
CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the ap...
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
Scopus BioPharma Inc. Website:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...